Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc. (NASDAQ: CRDL / TSX: CRDL) is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease. The company’s lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation—a process central to the development and progression of inflammation and fibrosis in pericarditis, myocarditis, and heart failure. The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

Cardiol’s MAVERIC Program is evaluating CardiolRx™ for recurrent pericarditis, comprising the completed Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial (NCT06708299), which is currently recruiting. The ARCHER Program studied CardiolRx™ in acute myocarditis, with Phase II results published in ESC Heart Failure and accepted for publication in the Journal of the American Heart Association.

The company is also developing CRD-38, a novel subcutaneously administered drug formulation targeting inflammatory heart disease including heart failure. Near-term catalysts include continued enrollment in the Phase III MAVERIC trial and advancement of the CRD-38 program.